Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Livongo Health, Inc.    LVGO

LIVONGO HEALTH, INC.

(LVGO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Livongo Health, Inc. : The underlying trend is in force again

10/14/2020 | 08:14am EST
10/14/2020 | 08:14am EST
long trade
Live
Entry price : 149.34$ | Target : 176$ | Stop-loss : 133$ | Potential : 17.85%
Livongo Health, Inc. shares show a positive technical situation which suggests a continuation of the upward dynamic over the medium term.
Investors have an opportunity to buy the stock and target the $ 176.
Livongo Health, Inc. : Livongo Health, Inc. : The underlying trend is in force again
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The tendency within the weekly time frame is positive above the technical support level at 57.21 USD

Weaknesses
  • Low profitability weakens the company.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Based on current prices, the company has particularly high valuation levels.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Subsector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalization (M$)Investor Rating
LIVONGO HEALTH, INC.457.74%14 020
-
ABBOTT LABORATORIES24.59%191 805
MEDTRONIC PLC0.22%152 480
BECTON, DICKINSON AND COMPA..-13.65%68 111
HOYA CORPORATION33.11%49 894
BAXTER INTERNATIONAL INC.-9.03%38 858
ALIGN TECHNOLOGY, INC.72.48%37 950
SARTORIUS STEDIM BIOTECH105.15%33 382
ZIMMER BIOMET HOLDINGS-0.37%30 909
DEXCOM, INC.46.15%30 698
TERUMO CORPORATION6.74%30 026
More Results

© Zonebourse.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 - - -
Net income 2020 - - -
Net cash 2020 294 M - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 14 199 M 14 199 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 615
Free-Float 93,6%
Upcoming event on LIVONGO HEALTH, INC.
Income Statement Evolution
Managers
NameTitle
Karl Greiter Senior Vice President-Operations
David Engberg Chief Technology Officer
Bimal Shah Chief Medical Officer
Whitney Mirro Senior Vice President-Clinical Services
Hemant Taneja Independent Director